NCT06205836 2026-03-17
Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
Clinical Trials
18 trialsNCT07332000 2026-03-17
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
Candel Therapeutics, Inc.
Phase 2 Recruiting
NCT00417495 2026-03-16
IGASSU
Centre Oscar Lambret
Phase 2 Completed
NCT05968326 2026-03-12
IMCODE003
Genentech, Inc.
Phase 2 Recruiting
NCT06957691 2026-03-09
Fezo-ADT
Brigham and Women's Hospital
Phase 2 Recruiting
NCT05672524 2026-03-04
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05063565 2026-03-02
ROWAN
Boston Scientific Corporation
Phase 2 Active not recruiting
NCT05014776 2026-02-24
Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT04379596 2026-02-23
DG-03
AstraZeneca
Phase 2 Recruiting
NCT07259317 2026-02-20
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Corcept Therapeutics
Phase 2 Recruiting
NCT06616597 2026-02-19
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT06693128 2026-01-28
Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer
Ruijin Hospital
Phase 2 Active not recruiting
NCT07368985 2026-01-27
Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer
Erasmus Medical Center
Phase 2 Not yet recruiting
NCT05620628 2026-01-21
Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)
Samsung Medical Center
Phase 2 Recruiting
NCT06967987 2026-01-21
BEMAFLOT
Institut Cancerologie de l'Ouest
Phase 2 Withdrawn
NCT05208944 2026-01-20
THIO Sequenced With Cemiplimab in Advanced NSCLC
Maia Biotechnology
Phase 2 Recruiting
NCT07302451 2026-01-06
REDI-CaP
National Cancer Institute, Naples
Phase 2 Active not recruiting
NCT02864992 2025-12-23
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
EMD Serono
Phase 2 Active not recruiting